Long-Term Sedation Effect of Cipepofol Compared to Dexmedetomidine in Patients Receiving Invasive Mechanical...

Area of Science:

• Critical Care Medicine
• Pharmacology
• Anesthesiology

Background:

• Cipepofol, a propofol analogue, is approved in China for critically ill patients requiring mechanical ventilation.
• Previous studies show cipepofol has a favorable safety profile and comparable outcomes to propofol.
• Limited data exists comparing cipepofol to dexmedetomidine for long-term mechanical ventilation sedation.

Purpose of the Study:

• To evaluate the efficacy and safety of cipepofol versus dexmedetomidine for long-term sedation in intensive care unit (ICU) patients.
• To compare sedation performance using the Richmond Agitation and Sedation Scale (RASS) target range.
• To assess potential advantages of cipepofol over dexmedetomidine.

Main Methods:

• A randomized controlled trial involving 142 adult patients requiring invasive mechanical ventilation (MV) for ≥24 hours.
• Patients received either cipepofol or dexmedetomidine (1:1 ratio) aiming for a RASS score of -2 to +1.
• Primary endpoint: proportion of time within the target RASS range.

Main Results:

• Cipepofol showed a trend towards more time within the target RASS range (99.7% vs. 98.8%), though not statistically significant after age adjustment.
• Cipepofol demonstrated significantly higher successful sedation rates (85.1% vs. 50.0%) and early sedation success (81.1% vs. 64.7%).
• Cipepofol was associated with less bradycardia (16.2% vs. 32.4%) and no significant differences in other adverse events or clinical outcomes.

Conclusions:

• Cipepofol is a safe and effective alternative for long-term sedation in Chinese ICU patients on mechanical ventilation.
• Sedation performance is comparable to dexmedetomidine, with potential benefits in stability and reduced need for rescue therapy.
• Early achievement of sedation goals without hypotension may be linked to improved long-term outcomes, warranting further investigation.